Radiopharm Theranostics Reports Business Update

Following a successful end-of-Phase 2 meeting with the FDA, a Phase 3 imaging trial of RAD101 for recurrent brain metastases from solid tumors is expected to begin in 1Q27. The update signals progress toward a later-stage trial, but provides no clinical results or other numerical data.